When out‐licencing a substance, there may be significant expenditures associated with remanufacturing the active product and placebo, completing research reports and regulatory paperwork, ensuring drug safety, monitoring patient safety and coordinating activities.
← all excerpts
From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases.
1
—
—